Cargando…

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment

BACKGROUND: We report a subgroup analysis of afatinib with respect to its efficacy, safety, and the long‐term survival of patients in a Named Patient Use program at a single institution. METHODS: We analyzed 60 patients with stage IV non‐small cell lung cancer (NSCLC) who had been treated with ≥1 li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Hayoung, Lee, Jae‐Kyeong, Oh, Hyung‐Joo, Kim, Min‐Seok, Kho, Bo Gun, Park, Cheol Kyu, Oh, In‐Jae, Kim, Young‐Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107028/ https://www.ncbi.nlm.nih.gov/pubmed/33811467 http://dx.doi.org/10.1111/1759-7714.13957

Ejemplares similares

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
por: Choi, Hayoung, et al.
Publicado: (2015)

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
por: Schuler, M., et al.
Publicado: (2016)

Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib
por: Chen, Gang, et al.
Publicado: (2013)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer
por: Fujiwara, Atsushi, et al.
Publicado: (2018)

Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
por: Kwok, Wang Chun, et al.
Publicado: (2022)

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
por: Jung, Hyun Ae, et al.
Publicado: (2023)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
por: Liang, Wenhua, et al.
Publicado: (2014)

Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population
por: SUTANDYO, Noorwati, et al.
Publicado: (2019)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis
por: You, Joyce H. S., et al.
Publicado: (2021)

Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity
por: Yamanaka, Yumie, et al.
Publicado: (2017)

Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis
por: Yoon, Byung Woo, et al.
Publicado: (2019)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
por: Cho, Kyoung Min, et al.
Publicado: (2015)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Case of Proteinuria, Worsening Hypertension, and Glomerular Endotheliosis With Erlotinib and Gefitinib
por: Latcha, Sheron, et al.
Publicado: (2018)

Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
por: Jung, Minkyu, et al.
Publicado: (2012)

Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data
por: Brzozowska, Melania, et al.
Publicado: (2019)

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
por: Wong, Matthew K., et al.
Publicado: (2009)

Risk factors for cerebral complications in patients with pulmonary arteriovenous malformations: A multicenter retrospective cohort study
por: Na, Young-Ok, et al.
Publicado: (2022)

Serum KL-6 levels predict the occurrence and severity of treatment-related interstitial lung disease in lung cancer
por: Park, Hwa Kyung, et al.
Publicado: (2023)

Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report
por: Park, Cheol Kyu, et al.
Publicado: (2017)

Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer
por: Hong, Junshik, et al.
Publicado: (2010)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer
por: Song, Si Yeon, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer
por: Park, Seongho, et al.
Publicado: (2019)

Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
por: Park, Cheol‐Kyu, et al.
Publicado: (2020)

Myasthenia gravis and myopathy after nivolumab treatment for non‐small cell lung carcinoma: A case report
por: Kim, Je‐Seong, et al.
Publicado: (2019)

Rapid Response to High-Dose, Pulsatile Erlotinib in Afatinib-Refractory Leptomeningeal Carcinomatosis from Adenocarcinoma of the Lung: A Case Report
por: Fan, Frank S.
Publicado: (2016)

Clinical characteristics and prognosis of patients with Pneumocystis jirovecii pneumonia without a compromised illness
por: Kim, Tae-Ok, et al.
Publicado: (2021)

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
por: Schuler, Martin, et al.
Publicado: (2019)

Treatment with gefitinib after erlotinib-induced liver injury: a case report
por: Nakatomi, Katsumi, et al.
Publicado: (2011)

Erlotinib and gefitinib treatments of the lung cancer in an elderly patient result in gastrointestinal bleeding
por: Bai, Hongmei, et al.
Publicado: (2013)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer
por: Park, Cheol-Kyu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vt7is7m89u65lhjsapbs0frumh